Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis

Critical Care Medicine

Volumn 34, Issue 1, 2006, Pages 240-241

  Dager, William E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug removal; Extended duration hemodialysis; Hemodialysis; Meropenem; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; MEROPENEM; VANCOMYCIN;

ACUTE KIDNEY FAILURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; EDITORIAL; EXTENDED DAILY DIALYSIS; HUMAN; PRIORITY JOURNAL;

EID: 29744453305     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000190903.21395.7F     Document Type: Editorial

References (5)

1. Kumar VA, Yuen JY, Depner TA, et al: Extended daily dialysis vs continuous hemodialysis for ICU patients with acute renal failure: A two-year single center report. Int J Artif Organs 2004; 27:371-379
2. Teehan GS, Liangos O, Jaber BL: Update on dialytic management of acute renal failure. J Intensive Care Med 2003; 18:130-138
3. Kielstein JT, Czock D, Schöpke T, et al: Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34:51-56
4. Thalhammer F, Hori WH: Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet 2000; 39:271-279
5. Smith PF, Morse GD: Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease. Ann Pharmacother 1999; 33:1329-1335